Comparative efficacy of repurposed drugs lopinavir-ritonavir and darunavir-ritonavir in hospitalised COVID-19 patients: insights from a tertiary centre cohort
BackgroundDrug repurposing has become a widely adopted strategy to minimise research time, costs, and associated risks. Combinations of protease inhibitors such as lopinavir and darunavir with ritonavir have been repurposed as treatments for COVID-19. Although lopinavir-ritonavir (LPV/r) and darunav...
Saved in:
Main Authors: | Dóra Paróczai, András Bikov, Andreea Blidaru, Emanuel Bobu, Ana Lascu, Cristian Ion Mot, Stefan Mihaicuta, Stefan Frent |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Cellular and Infection Microbiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2024.1496176/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Persistent hepatocyte secretory failure in lopinavir/ritonavir related to drug-induced liver injury: a case report
by: Yue Sun, et al.
Published: (2025-02-01) -
Effect of quercetin on the transport of ritonavir to the central nervous system in vitro and in vivo
by: Liang Gongwen, et al.
Published: (2016-03-01) -
Ritonavir loaded solid lipid nanoparticles for oral drug delivery and bioavailability enhancement
by: Ananda Kumar Chettupalli, et al.
Published: (2025-01-01) -
Stability indicating RP-HPLC technique for simultaneous estimation of nirmatrelvir and ritonavir in their new copackaged dosage form for COVID-19 treatment
by: Mohamed G. Yassin, et al.
Published: (2025-01-01) -
HPTLC Method for Simultaneous Determination of Lopinavir and Ritonavir in Capsule Dosage Form
by: A. V. Sulebhavikar, et al.
Published: (2008-01-01)